Tumor Immunology and Immunotherapy
-
10% KEDVEZMÉNY?
- A kedvezmény csak az 'Értesítés a kedvenc témákról' hírlevelünk címzettjeinek rendeléseire érvényes.
- Kiadói listaár GBP 237.50
-
113 465 Ft (108 062 Ft + 5% áfa)
Az ár azért becsült, mert a rendelés pillanatában nem lehet pontosan tudni, hogy a beérkezéskor milyen lesz a forint árfolyama az adott termék eredeti devizájához képest. Ha a forint romlana, kissé többet, ha javulna, kissé kevesebbet kell majd fizetnie.
- Kedvezmény(ek) 10% (cc. 11 347 Ft off)
- Kedvezményes ár 102 119 Ft (97 256 Ft + 5% áfa)
Iratkozzon fel most és részesüljön kedvezőbb árainkból!
Feliratkozom
113 465 Ft
Beszerezhetőség
Megrendelésre a kiadó utánnyomja a könyvet. Rendelhető, de a szokásosnál kicsit lassabban érkezik meg.
Why don't you give exact delivery time?
A beszerzés időigényét az eddigi tapasztalatokra alapozva adjuk meg. Azért becsült, mert a terméket külföldről hozzuk be, így a kiadó kiszolgálásának pillanatnyi gyorsaságától is függ. A megadottnál gyorsabb és lassabb szállítás is elképzelhető, de mindent megteszünk, hogy Ön a lehető leghamarabb jusson hozzá a termékhez.
A termék adatai:
- Kiadó OUP Oxford
- Megjelenés dátuma 2014. május 29.
- ISBN 9780199676866
- Kötéstípus Keménykötés
- Terjedelem470 oldal
- Méret 253x176x27 mm
- Súly 1076 g
- Nyelv angol 0
Kategóriák
Rövid leírás:
Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field.
TöbbHosszú leírás:
Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management.
Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity.
The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.
Overall, this book provides a good overview of cancer immunotherapy with specific insights into the main clinical treatments and experimental approaches for specialists.
Tartalomjegyzék:
Adaptive T-cell immunity and tumor antigen recognition
Impact of aging and body mass on cancer immunotherapy outcomes
The potential of natural killer cells in cancer immunotherapy
The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy
"Hard" and "soft" loss of MHC class I expression in cancer cells
Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses
Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation.
Triggering death receptors as a means of inducing tumoricidal activity
Identification of tumor antigens for clinical evaluation
Viral antigens as targets for prophylactic and therapeutic intervention in cancer
HER-2/neu as a target for vaccine and antibody directed therapies
Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model
Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
Predictive biomarkers to better select patients for cancer immunotherapy
Viral platforms for expression of tumour antigens in cancer immunotherapy
Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
DNA vaccines
Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA)
Vaccination against myeloid leukaemias using newly defined antigens
Immune-checkpoint blockade in cancer immunotherapy
Multi-peptide cancer vaccines for clinical application
Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma
Chimeric antigen receptor gene therapy in cancer
The vaccinal effect of monoclonal antibodies in cancer therapy
Antibody therapies: defining appropriate cell surface epitopes for targeting tumours
Adoptive lymphocyte (stem cell) therapy in cancer
Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy
Immune escape and aging of the immune system compromises the immune response to tumor antigens
